Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2021

View Archived Issues

Eli Lilly divulges new MRGPRX1 agonists

U.S. researchers patent TREM2 agonists

Merck & Co. synthesizes new LAAO inhibitors

Takeda Pharmaceutical identifies new 5-HT4 receptor agonists

Bristol Myers Squibb presents Gal-3 inhibitors

KCC2 shows promise as therapeutic target for neonatal seizures

Targeting senescent cells may fight insulin resistance

Discovery of the novel BCL6 BTB-specific inhibitor, AP-4-287

M-9657 shows mesothelin-dependent antitumoral activity in vivo

Novel silicon-containing cannabinoids show therapeutic efficacy in model of multiple sclerosis

Genmab presents preclinical data for DuoBody-CD3xB7H4 (GEN-1047)

Turnstone Biologics collaborates with Moffitt on preclinical TIL therapies

HotSpot Therapeutics closes financing to support Smart Allostery-driven pipeline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...